Expression and cisplatin sensitivity of copper-transporting P-type adenosine triphosphatase (ATP7B) in human solid carcinoma cell lines

Oncol Rep. 2001 Nov-Dec;8(6):1285-7. doi: 10.3892/or.8.6.1285.

Abstract

One of the most important clinical problems in the treatment of human solid carcinoma is the intrinsic/acquired resistance. Cisplatin is a platinum compound that is one of the most effective agents in clinic. Copper-transporting P-type adenosine triphosphate (ATP7B) has been reported to be associated with cisplatin resistance by the experiment of transfection of full cDNA of ATP7B into KB3-1 lacking ATP7B. We examined the relationship between mRNA expression level of ATP7B and sensitivity to cisplatin in nine human ovarian carcinoma cell lines to extend these findings. mRNA expression level of ATP7B was significantly correlated with cisplatin-sensitivity in nine cell lines, raising the possibility that ATP7B could be a chemoresistance marker in some types of human solid carcinoma.

MeSH terms

  • Adenosine Triphosphatases / biosynthesis*
  • Antineoplastic Agents / pharmacology*
  • Carcinoma / drug therapy*
  • Carcinoma / metabolism*
  • Cation Transport Proteins / biosynthesis*
  • Cisplatin / pharmacology*
  • Copper-Transporting ATPases
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor
  • Humans
  • RNA, Messenger / analysis
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Cation Transport Proteins
  • RNA, Messenger
  • Adenosine Triphosphatases
  • ATP7B protein, human
  • Copper-Transporting ATPases
  • Cisplatin